TransMedics Group Inc. logo

TransMedics Group Inc. (TMDX)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
82. 24
-2.63
-3.0989%
$
2.93B Market Cap
- P/E Ratio
- Div Yield
883,815 Volume
-0.93 Eps
$ 84.87
Previous Close
Add Transaction
Day Range
81.34 85.98
Year Range
60.1 156
Want to track TMDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TMDX closed today lower at $82.24, a decrease of -3.0989% from yesterday's close, completing a monthly increase of 4.5512% or $3.58. Over the past 12 months, TMDX stock lost -33.8162%.
TMDX is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2026, missed the consensus estimates by -0.63%. On average, the company has fell short of earnings expectations by -0.2231%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

TMDX Chart

People also search for

Kymera Therapeutics Inc.
$ 119.05
+0.202%
Protagonist Therapeutics Inc.
$ 146.49
-0.8528%
Apogee Therapeutics Inc.
$ 135.08
0%
Abivax SA ADR
$ 113.67
+1.7363%
Rhythm Pharmaceuticals Inc.
$ 104.74
-1.3097%
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.

Marketbeat | 2 weeks ago
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.

Zacks | 3 weeks ago
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

Seekingalpha | 4 weeks ago

TransMedics Group Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
71 $7,301.4 $5,430.79 -$1,870.61 -25.62%
BZ
Brandon Zatopek Commonwealth Equity Services LLC
10,074 $737,618.28 $845,107.86 $107,489.58 14.57%
PER
Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc.
13,380 $1.14M $1.2M $59,136.13 5.2%
JD
Jim Dushek HARBOUR INVESTMENTS Inc.
674 $51,520.1 $60,228.64 $8,708.54 16.9%
NA
Nizar Araji National Bank Of Canada /FI/
395 $47,663.24 $33,148.4 -$14,514.84 -30.45%

TransMedics Group Inc. (TMDX) FAQ

What is the stock price today?

The current price is $82.24.

On which exchange is it traded?

TransMedics Group Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is TMDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.93B.

Has TransMedics Group Inc. ever had a stock split?

No, there has never been a stock split.

TransMedics Group Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Waleed H. Hassanein CEO
NASDAQ (NMS) Exchange
89377M109 CUSIP
US Country
898 Employees
- Last Dividend
- Last Split
2 May 2019 IPO Date

Overview

TransMedics Group, Inc. is a pioneering commercial-stage medical technology company deeply invested in revolutionizing the therapy for patients suffering from end-stage organ failure across the globe, including in the United States. Founded in 1998, with its headquarters located in Andover, Massachusetts, TransMedics is dedicated to advancing the field of organ transplantation through its innovative Organ Care System (OCS). This cutting-edge system offers a dynamic approach to organ preservation, optimization, and monitoring by mimicking near-physiologic conditions outside the human body using specialized, proprietary technology. By pushing the boundaries of medical technology, TransMedics Group, Inc. seeks to improve the outcomes of organ transplants and broaden the range of viable organs available for transplantation, thus saving more lives and improving the quality of life for patients with life-threatening organ failures.

Products and Services

  • OCS LUNG

This product is designed for the preservation of standard criteria donor lungs intended for double-lung transplants. By maintaining the donor lungs in a near-physiologic state, the OCS LUNG system increases the potential pool of viable organs for transplantation, thereby addressing the critical shortage of transplantable lungs.

  • OCS Heart

OCS Heart is an advanced technology geared for the preservation of heartbeating donor (DBD) hearts that may be considered unsuitable because of the limitations associated with cold storage. The system additionally offers a unique capability for the ex vivo reanimation, functional monitoring, and beating-heart preservation of hearts from donors after circulatory death (DCD), effectively expanding the heart donor pool by utilizing organs that may not have been considered for transplantation previously.

  • OCS Liver

Geared towards the preservation of donor livers, including those from DBD and DCD donors, the OCS Liver system operates by recreating near-physiological conditions that sustain the liver outside of the human body. This technology is pivotal in increasing the usability of donated livers for transplantation, potentially reducing the waiting lists for liver transplants significantly.

  • National OCS Program

TransMedics has also established a national OCS program that acts as a comprehensive solution for organ retrieval. This includes outsourced services that cover the entire process of organ procurement, extending from aviation and ground transportation to various coordination activities, thus streamlining the organ transplantation logistics chain.

  • OCS Organ Management and Logistics Services

In addition to the innovative OCS technology, TransMedics provides a suite of organ management and logistics services. These services are designed to facilitate the complex process of organ transportation and management, ensuring that organs arrive at their destination in optimal condition ready for transplantation. This comprehensive service package includes aviation and ground transportation, among other critical coordination activities necessary for successful organ transplantation.

Contact Information

Address: 200 Minuteman Road
Phone: 978 552 0900